SES
23.4.2020 08:52:11 CEST | Business Wire | Press release
SES announced today that the number of global TV households it reaches directly or indirectly via satellite has increased by 12 million to 367 million in 2019. Findings from the company’s annual Satellite Monitor market research validates, once again, SES’s position as the world’s leading video content distributor via satellite and shows the important role that satellite continues to play in reaching the largest possible audience globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200422006137/en/
Much of the increase in the 12 million TV households is attributed to the leading infrastructure of TV reception – satellite and cable – which grew by 9 million in 2019 to 153 million and 149 million homes respectively. Internet Protocol TV (IPTV) and terrestrial TV grew by a combined 3 million to 43 million and 21 million homes.
The Satellite Monitor study also showed that SES’s technical reach has increased across several continents, including Europe, Africa, Asia-Pacific (APAC), and Latin America (LATAM). Europe continues to be the strongest market for SES, with 168 million total households served by the SES fleet, up by 1 million from 2018, followed by North America at 69 million.
In LATAM, SES has captured an audience of 42 million households, a significant increase from the 34 million households reported in 2018, thanks in part to the launch of a new satellite – SES 14 – which is boosting cable and IPTV growth in the region. This year also marked the first year that SES collected results from Indonesia and the Philippines. In total, SES serves 39 million APAC households with Direct-to-Home (DTH) feeds. The research also found that SES delivers digital television to 13 million households in the Middle East and 35 million homes in Africa. Altogether, SES has observed a combined growth of almost 5 million households across APAC and Africa.
SES’s TV market research sheds light on several key trends behind the relevance of satellite broadcasting, including the transition from analog to digital TV and the rise of HD broadcast. End consumers in Ghana and Nigeria are choosing satellite TV for its better value proposition and free-to-air offerings, rather than purchasing new hardware and switching to digital terrestrial TV. The Satellite Monitor study also revealed that HD broadcast has been on the rise in Europe, with 167 million TV households, an increase of 5 million from 2018. Satellite remains the preferred choice of infrastructure when it comes to HD content broadcasting, underscoring the key value proposition of satellite broadcasting as a reliable and cost-effective video delivery to large audiences.
“Broadcasters and TV platform operators need robust and reliable data before they make the decision to enter new markets. For more than 25 years, SES has been the only satellite-based solutions provider in the world to regularly and extensively monitor the industry in specific countries and identify key trends for our customers to help them succeed in their business and expand their reach,” said Ferdinand Kayser, CEO at SES Video. “The results of our annual Satellite Monitor market research demonstrate that satellite continues to be the most optimal infrastructure to deliver high picture quality, and that despite changing consumption habits, people still strongly rely on linear TV and complement it with OTT content.”
Introduced in 1994, SES’s annual Satellite Monitor research reveals the detailed technical reach of SES and valuable insights into the video market and trends worldwide. It is seen as an important tool for SES’s customers, the leading broadcasters and content owners.
Follow us on:
Social Media
Blog
Media Library
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200422006137/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
